4152 Taiwan Liposome

TLC to Present at Upcoming Virtual Investor Conferences

TLC to Present at Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company’s management team will be presenting at the following virtual investor conferences:

HC Wainwright & Co Global Life Sciences Conference (March 9-10, 2021)

Presentation: on-demand starting 7am ET, Tuesday, March 9, 2021

Oppenheimer 31st Annual Healthcare Conference (March 16-17, 2021)

Presentation: 8am ET, Wednesday, March 17, 2021

The management team will also be participating in one-on-one meetings during the conference. The corporate presentation will be available on the TLC website at in the Investors section, under News & Events.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of a diverse, wholly owned portfolio of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval. Other risks are described in the Risk Factors section of TLC’s annual report on Form 20-F for the year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLC’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.



Contact
Dawn Chi / Corporate Communications /  
EN
02/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Taiwan Liposome

 PRESS RELEASE

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Break...

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Professor David Hunter, Florance and Cope Chair of Rheumatology at the University of Sydney, presented detailed findings from the Phase 3 clinical trial of TLC599 at the American College of Rheumatology (ACR) Annual Meeting last week. TLC599 is an investigational therapy developed by TLC BioSciences for osteoarthritis knee pain. In his late-breaking oral presentation, Prof. Hunter provided background on osteoarthritis...

 PRESS RELEASE

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Sessi...

TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 08, 2023 (GLOBE NEWSWIRE) --  (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the Abstract Selection Committee of the American College of Rheumatology (ACR) has accepted TLC's late-breaking abstract on TLC599 for oral presentation at ACR Con...

 PRESS RELEASE

TLC Announces TLC599 Agreement with Endo

TLC Announces TLC599 Agreement with Endo One of the largest deals seen in Taiwan’s biotech sector SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has entered a commercialization agreement with (Nasdaq: ENDP) for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain. Under the terms of the ...

 PRESS RELEASE

TLC BioSciences Announces Publication of TLC599 Phase II Results in Ar...

TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy TLC599 reduces pain and improves function for up to 24 weeks, longer than existing intraarticular treatments, and significantly reduces oral medication use SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have...

 PRESS RELEASE

TLC Announces Voluntary Delisting and Deregistration of American Depos...

TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares This communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any relevant securities laws of any state or other jurisdiction of the United States. Such securities will be issued in reliance upon the exemption from th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch